Bivalirudin during primary PCI in acute myocardial infarction


Stone, GW; Witzenbichler, B; Guagliumi, G; Peruga, JZ; Brodie, BR; Dudek, D; Kornowski, R; Hartmann, F; Gersh, BJ; Pocock, SJ; Dangas, G; Wong, SC; Kirtane, AJ; Parise, H; Mehran, R; HORIZONS-AMI Trial Investigators, ; , COLLABORATORS; Stone, GW; Brodie, BR; Cox, A; Grines, CL; Rutherford, BD; Bhatt, D; Dangas, G; Ohman, M; Bonnier, H; Colombo, A; Garcia, E; Grube, E; Guagliumi, G; Kastrati, A; Serruys, P; Suryapranata, H; Bonnier, H; Suryapranata, H; Colombo, A; Guagliumi, G; Garcia, E; Grube, E; Kastrati, A; Almagor, Y; Banning, A; Belardi, J; Grinfeld, L; Dudek, D; Huber, K; Nilsen, D; Olivecrona, G; Rasmussen, L; Wong, SC; Farkouh, M; Attubato, M; Dangas, G; Feit, F; Mehran, R; Tyson, J; Winsted, D; Mehran, R; Bihl, I; Parise, H; Gersh, BJ; Faxon, D; King, S; Pocock, SJ; Williams, DO; Lansky, AJ; Cristea, E; Reiffel, J; Mintz, G; (2008) Bivalirudin during primary PCI in acute myocardial infarction. The New England journal of medicine, 358 (21). pp. 2218-30. ISSN 0028-4793 DOI: https://doi.org/10.1056/NEJMoa0708191

[img]
Preview
Text - Published Version
License: Copyright the publishers

Download (281kB) | Preview

Abstract

: Treatment with the direct thrombin inhibitor bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while reducing hemorrhagic complications in patients with stable angina and non-ST-segment elevation acute coronary syndromes who are undergoing percutaneous coronary intervention (PCI). The safety and efficacy of bivalirudin in high-risk patients are unknown.<br/> : We randomly assigned 3602 patients with ST-segment elevation myocardial infarction who presented within 12 hours after the onset of symptoms and who were undergoing primary PCI to treatment with heparin plus a glycoprotein IIb/IIIa inhibitor or to treatment with bivalirudin alone. The two primary end points of the study were major bleeding and combined adverse clinical events, defined as the combination of major bleeding or major adverse cardiovascular events, including death, reinfarction, target-vessel revascularization for ischemia, and stroke (hereinafter referred to as net adverse clinical events) within 30 days.<br/> : Anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, resulted in a reduced 30-day rate of net adverse clinical events (9.2% vs. 12.1%; relative risk, 0.76; 95% confidence interval [CI] 0.63 to 0.92; P=0.005), owing to a lower rate of major bleeding (4.9% vs. 8.3%; relative risk, 0.60; 95% CI, 0.46 to 0.77; P<0.001). There was an increased risk of acute stent thrombosis within 24 hours in the bivalirudin group, but no significant increase was present by 30 days. Treatment with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, resulted in significantly lower 30-day rates of death from cardiac causes (1.8% vs. 2.9%; relative risk, 0.62; 95% CI, 0.40 to 0.95; P=0.03) and death from all causes (2.1% vs. 3.1%; relative risk, 0.66; 95% CI, 0.44 to 1.00; P=0.047).<br/> : In patients with ST-segment elevation myocardial infarction who are undergoing primary PCI, anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events. (ClinicalTrials.gov number, NCT00433966 [ClinicalTrials.gov].).<br/>

Item Type: Article
Keywords: ACUTE CORONARY SYNDROMES, GLYCOPROTEIN IIB/IIIA BLOCKADE, RANDOMIZED, CONTROLLED-TRIAL, CLINICAL-OUTCOMES, ACUITY TRIAL, BLOOD-TRANSFUSION, INTERVENTION, ABCIXIMAB, THERAPY, IMPACT
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Medical Statistics
PubMed ID: 18499566
Web of Science ID: 256023600004
URI: http://researchonline.lshtm.ac.uk/id/eprint/7561

Statistics


Download activity - last 12 months
Downloads since deposit
469Downloads
293Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item